ES2994966T3 - Single doses of oritavancin for treating or preventing a bacterial infection - Google Patents

Single doses of oritavancin for treating or preventing a bacterial infection Download PDF

Info

Publication number
ES2994966T3
ES2994966T3 ES15195726T ES15195726T ES2994966T3 ES 2994966 T3 ES2994966 T3 ES 2994966T3 ES 15195726 T ES15195726 T ES 15195726T ES 15195726 T ES15195726 T ES 15195726T ES 2994966 T3 ES2994966 T3 ES 2994966T3
Authority
ES
Spain
Prior art keywords
oritavancin
bacterial infection
staphylococcus aureus
subject
prophylaxis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15195726T
Other languages
English (en)
Spanish (es)
Inventor
Dario Lehoux
Thomas Parr
Gregory Moeck
Pierre Etienne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Melinta Therapeutics LLC
Original Assignee
Melinta Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41722337&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2994966(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Melinta Therapeutics LLC filed Critical Melinta Therapeutics LLC
Application granted granted Critical
Publication of ES2994966T3 publication Critical patent/ES2994966T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
ES15195726T 2008-08-30 2009-08-29 Single doses of oritavancin for treating or preventing a bacterial infection Active ES2994966T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9331408P 2008-08-30 2008-08-30
US9349708P 2008-09-02 2008-09-02

Publications (1)

Publication Number Publication Date
ES2994966T3 true ES2994966T3 (en) 2025-02-04

Family

ID=41722337

Family Applications (2)

Application Number Title Priority Date Filing Date
ES15195726T Active ES2994966T3 (en) 2008-08-30 2009-08-29 Single doses of oritavancin for treating or preventing a bacterial infection
ES09810708T Active ES2570401T3 (es) 2008-08-30 2009-08-29 Métodos de tratamiento usando dosis únicas de oritavancina

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES09810708T Active ES2570401T3 (es) 2008-08-30 2009-08-29 Métodos de tratamiento usando dosis únicas de oritavancina

Country Status (18)

Country Link
US (2) US8420592B2 (enExample)
EP (3) EP2337575B1 (enExample)
JP (1) JP5782615B2 (enExample)
CN (2) CN102215858A (enExample)
AU (1) AU2009285564B2 (enExample)
CA (1) CA2736860C (enExample)
DK (2) DK2337575T3 (enExample)
EA (1) EA020490B1 (enExample)
ES (2) ES2994966T3 (enExample)
FI (1) FI3006038T3 (enExample)
HU (3) HUE027373T2 (enExample)
MX (1) MX2011002249A (enExample)
NL (1) NL300834I2 (enExample)
NO (1) NO2016019I2 (enExample)
NZ (1) NZ591525A (enExample)
PL (2) PL3006038T3 (enExample)
PT (1) PT3006038T (enExample)
WO (1) WO2010025438A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5782615B2 (ja) * 2008-08-30 2015-09-24 ザ メディシンズ カンパニー オリタバンシンの単回用量を用いる治療の方法
PT2424559T (pt) 2009-04-28 2024-04-30 Melinta Therapeutics Llc Métodos de tratamento de infeções bacterianas utilizando oritavancina
WO2014031681A1 (en) * 2012-08-20 2014-02-27 The University Of Chicago Inhibiting gram positive bacteria
WO2014176068A2 (en) * 2013-04-22 2014-10-30 The Medicines Company Treatment and prevention of bacterial skin infections using oritavancin
LT3038616T (lt) 2013-08-26 2023-05-25 Melinta Therapeutics, Inc. Bakteriemijos ir osteomielito gydymo būdai naudojant oritavanciną
EP3038615A4 (en) * 2013-08-28 2017-04-12 The Medicines Company Methods for treating bacterial infections using oritavancin and polymyxins
US20170119793A1 (en) * 2014-06-12 2017-05-04 Cem-102 Pharmaceuticals, Inc. Compositions and methods for treating bone and joint infections
MX385925B (es) * 2014-07-17 2025-03-18 The Medicines Co Oritavancina de alta pureza y método para producir la misma.
CA3014294A1 (en) 2016-02-18 2017-08-24 Melinta Therapeutics, Inc. Oritavancin formulations
WO2017179003A1 (en) * 2016-04-15 2017-10-19 Lupin Limited Topical compositions for ophthalmic and otic use
CN108409837B (zh) * 2018-03-06 2021-09-24 上海来益生物药物研究开发中心有限责任公司 一组具有抗耐药性细菌活性的糖肽类化合物、其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840684A (en) 1994-01-28 1998-11-24 Eli Lilly And Company Glycopeptide antibiotic derivatives
US5994297A (en) * 1997-08-22 1999-11-30 Eli Lilly And Company Therapy for Staphylococcus aureus
SK285970B6 (sk) * 1999-05-03 2007-12-06 Eli Lilly And Company Použitie N DISACC-(4-(4-chlórfenyl)benzyl)A82846Balebo teikoplanínu na prípravu liečiva na dlhodobú prevenciu infekcií Streptococcus pneumoniae a farmaceutické kompozície s ich obsahom
DE60136926D1 (de) 2000-05-02 2009-01-22 Theravance Inc Zusammensetzung die eine zyklodextrin und ein glykopeptid-antibiotikum enthält
US20030176327A1 (en) * 2001-10-25 2003-09-18 Cassell Gail Houston Antibiotics for treating biohazardous bacterial agents
WO2003102171A1 (en) * 2002-05-28 2003-12-11 Becton, Dickinson And Company Expansion and transdifferentiation of human acinar cells
WO2004017925A2 (en) 2002-08-23 2004-03-04 Genome Therapeutics Corporation Methods and reagents for preventing bacteremias
US20040127403A1 (en) * 2002-09-06 2004-07-01 Francesco Parenti Methods for treating and preventing Gram-positive bacteremias
US20070249577A1 (en) * 2005-05-10 2007-10-25 Hopkins Scott J Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures
CA2664444C (en) * 2006-09-25 2015-10-27 Melinta Therapeutics, Inc. Use of oritavancin for prevention and treatment of anthrax
JP5782615B2 (ja) 2008-08-30 2015-09-24 ザ メディシンズ カンパニー オリタバンシンの単回用量を用いる治療の方法
PT2424559T (pt) * 2009-04-28 2024-04-30 Melinta Therapeutics Llc Métodos de tratamento de infeções bacterianas utilizando oritavancina
EP3038615A4 (en) * 2013-08-28 2017-04-12 The Medicines Company Methods for treating bacterial infections using oritavancin and polymyxins

Also Published As

Publication number Publication date
JP2012501349A (ja) 2012-01-19
EP2337575A4 (en) 2012-10-17
DK3006038T3 (da) 2024-08-26
JP5782615B2 (ja) 2015-09-24
WO2010025438A9 (en) 2010-05-14
AU2009285564B2 (en) 2014-05-22
EP3006038B1 (en) 2024-07-03
NO2016019I2 (no) 2019-01-25
EA201100413A1 (ru) 2012-01-30
EP2337575A1 (en) 2011-06-29
HUE068423T2 (hu) 2024-12-28
EP3006038A1 (en) 2016-04-13
CN106620649A (zh) 2017-05-10
EA020490B1 (ru) 2014-11-28
PL3006038T3 (pl) 2024-11-12
FI3006038T3 (fi) 2024-08-12
DK2337575T3 (en) 2016-05-23
US20110201546A1 (en) 2011-08-18
CA2736860A1 (en) 2010-03-04
US20130172237A1 (en) 2013-07-04
US12514899B2 (en) 2026-01-06
WO2010025438A2 (en) 2010-03-04
EP2337575B1 (en) 2016-04-13
EP4464375A2 (en) 2024-11-20
NO2016019I1 (no) 2016-10-11
NL300834I2 (enExample) 2016-11-16
NZ591525A (en) 2014-03-28
PT3006038T (pt) 2024-08-23
HUS1600039I1 (hu) 2016-11-28
ES2570401T3 (es) 2016-05-18
CN102215858A (zh) 2011-10-12
US8420592B2 (en) 2013-04-16
MX2011002249A (es) 2011-06-24
EP4464375A3 (en) 2025-02-26
AU2009285564A1 (en) 2010-03-04
PL2337575T3 (pl) 2016-09-30
CA2736860C (en) 2020-04-28
HUE027373T2 (hu) 2016-09-28

Similar Documents

Publication Publication Date Title
DK2337575T3 (en) A method of treatment with single doses of oritavancin
US8778873B2 (en) Parenteral combination therapy for infective conditions with drug resistant bacterium
UA121298C2 (uk) Антибіотична композиція на основі цефтолозану і тазобактаму
ES2981472T3 (es) Procedimientos para el tratamiento de infecciones bacterianas utilizando oritavancina
BRPI0916885B1 (pt) composição farmacêutica
KR20200026118A (ko) 헬리코박터 파일로리 제균용 조성물
ES2445941T3 (es) Uso de oritavancina para la prevención y el tratamiento del ántrax
US20230364065A1 (en) Antibiotic combination therapies
US20160101148A1 (en) Treatment and prevention of bacterial skin infections using oritavancin
EP3038615A2 (en) Methods for treating bacterial infections using oritavancin and polymyxins
KR20140117523A (ko) 아목시실린 및 클라불란산 칼륨의 소아용 경구 현탁 제형 및 이를 사용하기 위한 방법
AU2013202360B2 (en) Methods of treatment using single doses of oritavancin
EP3270925B1 (en) Antibacterial compositions
BRPI0816662B1 (pt) Método in vitro para inibir crescimento de esporo de c. difficile